Delivery of sedative-hypnotics through an inhalation route
First Claim
1. A composition for delivery of a sedative-hypnotic compound comprising a condensation aerosol(a) formed by volatilizing a sedative-hypnotic compound selected from the group consisting of zaleplon, zolpidem and zopiclone under conditions effective to produce a heated vapor of the compound, and condensing the heated vapor of the compound to form condensation aerosol particles, and (b) wherein said condensation aerosol particles are characterized by less than 5% compound degradation products, and (c) aerosol MMAD is less than 3 μ
- m.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a sedative-hypnotic. In a method aspect of the present invention, a sedative-hypnotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of a sedative-hypnotic; and, b) a device that forms a sedative-hypnotic containing aerosol from the composition, for inhalation by the mammal.
135 Citations
10 Claims
-
1. A composition for delivery of a sedative-hypnotic compound comprising a condensation aerosol
(a) formed by volatilizing a sedative-hypnotic compound selected from the group consisting of zaleplon, zolpidem and zopiclone under conditions effective to produce a heated vapor of the compound, and condensing the heated vapor of the compound to form condensation aerosol particles, and (b) wherein said condensation aerosol particles are characterized by less than 5% compound degradation products, and (c) aerosol MMAD is less than 3 μ
-
5. A method of producing a sedative-hypnotic compound zaleplon, zolpidem or zopiclone in an aerosol form comprising
a) volatilizing a sedative-hypnotic compound selected from the group consisting of zaleplon, zolpidem and zopiclone under conditions effective to produce a heated vapor of the compound, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the compound comprising less than 5% compound degradation products, and c) aerosol MMAD is less than 3 μ
Specification